Generic placeholder image

Protein & Peptide Letters


ISSN (Print): 0929-8665
ISSN (Online): 1875-5305

Research Article

Truncated JFH1 E2 Protein: Is it Reliable to be Used in Diagnostic ELISA Test and as a Protein-Based Vaccine Candidate?

Author(s): Sara Bagheri, Pooneh Rahimi*, Rouhollah Vahabpour, Fatemeh Motevalli, Mohammad Shayestehpour, Mohammad Reza Amiran and Shaghayegh Yazdani

Volume 24, Issue 12, 2017

Page: [1179 - 1184] Pages: 6

DOI: 10.2174/0929866524666171009164314

Price: $65


Background: HCV E2 glycoprotein is one of the most attractive proteins for designing an effective vaccine. Deletion of hydrophobic carboxyl-terminal region of this protein is necessary for its secretion, especially when it is expressed in E-coli. In this study we expressed this protein in truncated form and evaluated its application in developing an ELISA test and induction of humoral response in immunized mice.

Objectives: The purpose of this study was expression of HCV truncated E2 protein from JFH1 strain in E-coli BL21(DE3) and evaluation of its antigenicity.

Methods: Truncated E2 region from HCV genotype 2a (JFH1) was amplified by PCR and cloned into a pET28a (+) vector and was used to transform the E-coli DH5α strain. The recombinant E2 protein was evaluated both in an ELISA test and induction of humoral immunity in mice.

Results: Truncated E2 protein was expressed in BL21(DE3). Its specific antibody was detected in serum samples from HCV infected patients. Also, it could elicit a significant humoral immunity in mice.

Conclusion: Truncated form of E2 protein which has been expressed in E-coli could be used as an effective antigen both in diagnostic tests such as ELISA and also, as a protein-based vaccine candidate.

Keywords: HCV E2 glycoprotein, E. coli BL21(DE3), JFH1 strain, ELISA test, Protein-based vaccine, antigenicity.

Graphical Abstract

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy